HJ Heinz Co. (NYSE:HNZ): Following Heinz’s report of lower than expected revenue, Argus believes that the company will benefit from studying inflation pressures and its investments in emerging markets. The firm views the stock as undervalued and keeps a Buy rating.
Don’t Miss: Apple and Google CEOs Keep the Phone Lines OPEN.
Apple Inc. (NASDAQ:AAPL): According to KGI Securities, Apple has been forced to postpone incorporating additional advanced panel/ touch technologies in its products because of supply constraints. Consequently, the firm lowered its estimate for iPhone 5 shipments to 10 million from 16 million during Q3 and to 35 million from 48 million during Q4. The firm still expects the company to be the head in panel technology for another one to two years when the “growing pains” subside.
Onyx Pharmaceuticals Inc. (NASDAQ:ONXX) and Bayer (BAYRY) announced that Bayer has submitted an NDA to the FDA for regorafenib intended for the treatment of metastatic and/or unresectable gastrointestinal stromal tumors for particular patients, Rodman & Renshaw believe that the FDA will approve the drug for later-line metastatic colorectal cancer in October 2012. The firm believes there will be a regorafenib launch in 1Q13 in the U.S. and nearly $50MM in regorafenib sales in 2013, and it reiterates an Outperform rating on the stock.
support.com, Inc. (NASDAQ:SPRT): Following Sarepta’s increase of more than 15 percent today due to a report that the company’s drug had improved the quality of life of a 12 year old with Duchenne Muscular Dystrophy, Rodman & Renshaw keeps its Outperform rating and its $12 target on the stock.
Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD): Caris recommends buying Ironwood Pharmaceuticals shares at current levels since investors await pricing and labeling information for the company’s recently approved irritable bowel syndrome treatment.
Don’t Miss: Here’s Why the News Gets BAD for Facebook.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>